Halofuginone

Drug Profile

Halofuginone

Alternative Names: Halofuginone hydrobromide; HT-100; Stenorol™; Tempostatin™

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Collgard Biopharmaceuticals
  • Developer Akashi Therapeutics; Collgard Biopharmaceuticals
  • Class Antifibrotics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scleroderma; Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma

Most Recent Events

  • 30 Aug 2016 Phase-II development in Duchenne muscular dystrophy is ongoing in USA (PO)
  • 08 Jan 2016 Halofuginone sub-licensed to Grunenthal for development worldwide and commercialisation in Europe and Latin America
  • 18 Jun 2015 Interim efficacy and safety data from a phase I/IIa trial in Duchenne muscular dystrophy released by Akashi Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top